Lund B, Sørensen O H, Lund B, Bishop J E, Norman A W
J Clin Endocrinol Metab. 1980 Sep;51(3):606-10. doi: 10.1210/jcem-51-3-606.
Only moderately reduced serum 1,25-dihydroxyvitamin D [1,25(OH)2D3] levels were found in 13 hypoparathyroid patients and in 1 pseudohypoparathyroid patient, indicating that factors other than parathyroid hormone are able to mediate the basal production of 1,25(OH)2D3. A significant correlation was found between the levels of circulating 25-hydroxyvitamin D (25OHD) and 1,25(OH)2D, suggesting that a high concentration of 25OHD was able to increase the renal production of 1,25(OH)2D, whereas hypocalcemia and changes in serum phosphate became less important in the present situation. The serum 25OHD and 1,25(OH)2D concentrations were followed during the change of treatment from ergocalciferol to 1 alpha-hydroxycholecalciferol (1 alpha-OHD3). A biological half-life of 3 weeks could be estimated for the plasma 25OHD. The increase in serum 1,25(OH)2D correlated with the dose of 1 alpha-OHD3 given, whereas no correlation was found between the serum calcium level and the 1,25(OH)2D concentration. Unexpected increases and decreases in serum calcium were observed at the same dose of 1 alpha-OHD3 in the same patient and at serum 1,25(OH)2D concentrations within the physiological range.
在13例甲状旁腺功能减退患者和1例假性甲状旁腺功能减退患者中,仅发现血清1,25 - 二羟维生素D [1,25(OH)₂D₃]水平中度降低,这表明除甲状旁腺激素外的其他因素能够介导1,25(OH)₂D₃的基础生成。循环中的25 - 羟维生素D(25OHD)水平与1,25(OH)₂D之间存在显著相关性,提示高浓度的25OHD能够增加肾脏对1,25(OH)₂D的生成,而在当前情况下低钙血症和血清磷酸盐变化的影响较小。在从麦角钙化醇改为1α - 羟胆钙化醇(1α - OHD₃)治疗的过程中,对血清25OHD和1,25(OH)₂D浓度进行了跟踪监测。血浆25OHD的生物学半衰期估计为3周。血清1,25(OH)₂D的升高与给予的1α - OHD₃剂量相关,而血清钙水平与1,25(OH)₂D浓度之间未发现相关性。在同一患者使用相同剂量的1α - OHD₃且血清1,25(OH)₂D浓度处于生理范围内时,观察到血清钙出现意外的升高和降低。